Filter Results:
(1,141)
Show Results For
- All HBS Web
(1,141)
- People (1)
- News (318)
- Research (703)
- Events (5)
- Multimedia (14)
- Faculty Publications (414)
Show Results For
- All HBS Web
(1,141)
- People (1)
- News (318)
- Research (703)
- Events (5)
- Multimedia (14)
- Faculty Publications (414)
- December 2021
- Case
Should I Stay or Should I Go? Assessing Risk in Carlos Ghosn's International Escape
By: Eugene F. Soltes, Grace Liu and Muneeb Ahmed
In 2018, automotive tycoon Carlos Ghosn was arrested in Japan on financial misreporting charges, followed later by charges of improper payments and misappropriation of funds. Over a year later, still awaiting trial, Ghosn organized his escape from house arrest in Tokyo... View Details
Keywords: Crime and Corruption; Decision Making; Cost vs Benefits; Decision Choices and Conditions; Ethics; Cross-Cultural and Cross-Border Issues; Law; Courts and Trials; Rights; Risk and Uncertainty; Auto Industry; Japan
Soltes, Eugene F., Grace Liu, and Muneeb Ahmed. "Should I Stay or Should I Go? Assessing Risk in Carlos Ghosn's International Escape." Harvard Business School Case 122-051, December 2021.
- 16 Sep 2016
- News
Gaining Ground on ALS
Bucket Challenge to support the Phase 3 trial of a promising investigational drug that is designed to slow the loss of lung function and muscle strength in patients with ALS. “Clinical View Details
- 24 Sep 2020
- News
The Race for a Vaccine
proteins were created inside the human body. The company launched its first vaccine trial for a strain of avian influenza in 2015. If developing vaccines for widespread and endemic diseases has long been... View Details
- July 2003 (Revised February 2004)
- Background Note
M&A Legal Context: Standards Related to the Sale or Purchase of a Company
By: Carliss Y. Baldwin, Constance E. Bagley and James Quinn
Introduces students to the legal standards affecting officers and directors when selling or purchasing a company. Provides a practical understanding of the Revlon Standard, the Securities and Exchange Act of 1934, Rule 10b-5, and the legal criteria for a cause of... View Details
Keywords: Laws and Statutes; Law Enforcement; Government Legislation; Acquisition; Business Exit or Shutdown; Corporate Governance; Going Public; Courts and Trials
Baldwin, Carliss Y., Constance E. Bagley, and James Quinn. "M&A Legal Context: Standards Related to the Sale or Purchase of a Company." Harvard Business School Background Note 904-004, July 2003. (Revised February 2004.)
- 2003
- Chapter
La tragédie de la thalidomide: affaires judiciaries et résponses législatives, 1959-1971
By: Arthur A. Daemmrich
- December 2014 (Revised August 2015)
- Case
Improving Melanoma Screening: MELA Sciences
By: Regina E. Herzlinger, Kevin Schulman and Frédéric Dijols
MELA is a start-up medical device company looking to develop a novel technology to help physicians diagnose a deadly skin cancer, melanoma. The case reviews the FDA medical device development process, the development path pursued by MELA, and the regulatory and... View Details
- September 2017 (Revised February 2018)
- Case
Becton Dickinson: Global Health Strategy
By: Mark R. Kramer and Sarah Mehta
Becton, Dickinson and Company (BD) was a medical technology firm headquartered in Franklin Lakes, New Jersey, with 43,000 employees and 2016 revenues of $12.5 billion. For several years, the company had pursued developing products that created shared value, defined as... View Details
Keywords: Shared Value; Creating Shared Value; Odon Device; Medical Technology; Value Creation; Values and Beliefs; Philanthropy and Charitable Giving; Health; Health Care and Treatment; Health Testing and Trials; Emerging Markets; Social Issues; Competitive Strategy; Medical Devices and Supplies Industry; Africa; Asia; Middle East
Kramer, Mark R., and Sarah Mehta. "Becton Dickinson: Global Health Strategy." Harvard Business School Case 718-406, September 2017. (Revised February 2018.)
- 15 Jan 2018
- News
A Better Business Model for Fighting Cancer
- February 2020
- Supplement
Theranos: Who Has Blood on Their Hands? (B)
By: Nien-he Hsieh, Christina R. Wing and John Masko
This supplemental case tracks the results of the Colman and Taubman-Dye class action suit against Theranos as well as Theranos’ other legal challenges and chronicles the final demise of the company in 2019. View Details
Keywords: Health Testing and Trials; Corporate Accountability; Organizational Culture; Misleading and Fraudulent Advertising; Crime and Corruption; Entrepreneurship; Lawsuits and Litigation; Business Exit or Shutdown; Medical Devices and Supplies Industry; California; United States
Hsieh, Nien-he, Christina R. Wing, and John Masko. "Theranos: Who Has Blood on Their Hands? (B)." Harvard Business School Supplement 320-091, February 2020.
- 02 Jun 2011
- Research & Ideas
Signing at the Top: The Key to Preventing Tax Fraud?
end of the tax form, after the form has been filled out and, consequently, after the potential cheating has occurred. (It's analogous to a witness first testifying in a court trial View Details
- 01 Jun 2018
- News
Floor It
so that we can help get clinical trials done and move the pace of discovery even quicker.” How do they expect to get there? Here, a look at the accelerator’s model, which comprises four work streams, each... View Details
Keywords: Julia Hanna; illustration by Mengxin Li
- March 30, 2020
- Article
Why Is the U.S. Behind on Coronavirus Testing?
By: Stefan Thomke
Coronavirus testing is needed to address the uncertainty in making decisions about patient treatment, resource allocation, policy, and so much more. Answers to questions such as “When should we relax social distancing measures—and for whom?” or “How many ventilators... View Details
Keywords: Testing; Coronavirus; Culture; Trump; Data; Experiments; Health Pandemics; Health Testing and Trials; Government and Politics; United States
Thomke, Stefan. "Why Is the U.S. Behind on Coronavirus Testing?" Harvard Business Review Digital Articles (March 30, 2020).
- March 2023
- Case
Moderna
By: Marco Iansiti, Karim R. Lakhani, Hannah Mayer, Kerry Herman, Allison J. Wigen and Dave Habeeb
This multimedia case follows the story of Moderna and its entry into vaccine development in the wake of the COVID-19 pandemic. In summer 2020, Stephane Bancel, CEO of biotech firm Moderna, faces several challenges as his company races to develop a vaccine for COVID-19.... View Details
- 23 Aug 2020
- News
In the UK, She Leads the Search for a COVID Vaccine
stop to the spread of COVID-19 was daunting. “When I told my daughter I wasn’t sure I could do this, she looked at me and said, ‘Mum! If I’d said that you’d have given me all this lip about ‘don’t be under-confident, you’re just putting... View Details
- May 2023 (Revised June 2023)
- Supplement
Novartis (C): Reimagining Medicine
By: Ramon Casadesus-Masanell, Claudio Feser, Karolin Frankenberger and David Redaschi
This case unfolds around the first-ever approved personalized cancer treatment, how Novartis wrapped it into a new business model design, and how Novartis scaled it. Novartis — one of the largest pharmaceutical companies in the world — is, among other ventures,... View Details
Keywords: Health Testing and Trials; Health Care and Treatment; Business Model; Problems and Challenges; Pharmaceutical Industry; Switzerland
Casadesus-Masanell, Ramon, Claudio Feser, Karolin Frankenberger, and David Redaschi. "Novartis (C): Reimagining Medicine." Harvard Business School Supplement 723-445, May 2023. (Revised June 2023.)
- 16 Mar 2022
- Blog Post
Taking Your Shot in the Sports Industry with Adam Laitsas (MBA 2016), SVP, Head of Marketing for Madison Square Garden Sports
Three months into his new role as SVP, Head of Marketing at Madison Square Garden Sports (MSG), Adam Laitsas (MBA 2016) looked out from his office onto a place that is equal parts inspiring and familiar. For three years, Laitsas regularly... View Details
- 07 Aug 2000
- Research & Ideas
The Business of Biotech
the anatomical—basis of the disease." Genzyme, which currently has drugs in clinical trials for melanoma and breast cancer, hopes to have its first products on the market as early as 2004. "I think... View Details
- 22 Feb 2022
- News
Elevator Pitch: Good Vibrations
Illustration by Drue Wagner Illustration by Drue Wagner Bone Health Technologies Laura Yecies (MBA 1988), CEO Concept: OsteoBoost, a wearable vibration belt that is designed to treat osteopenia and prevent osteoporosis by reducing bone... View Details
- 2009
- Case
Innovamedica: Innovation in an Emerging Market
By: Roberto Charvel, Fernando Fabre and T. Putimahtama
Innovamedica was a medical start up with several state of the art devices such as a silicon substitute heart and other inventions. However, the founding scientist was struggling in attracting talent and fundraising and that had an impact on growth. View Details
Keywords: Biotech; Entrepreneurial Finance; Entrepreneurship; Start-up; Emergent Countries; Business Startups; Talent and Talent Management; Design; Corporate Entrepreneurship; Private Equity; Health Testing and Trials; Innovation and Invention; Managerial Roles; Biotechnology Industry; Latin America; North and Central America
Charvel, Roberto, Fernando Fabre, and T. Putimahtama. "Innovamedica: Innovation in an Emerging Market." Instituto Panamericano de Alta Dirección de Empresa (IPADE) Case (P)DGe-440, 2009.
- June 2008 (Revised July 2008)
- Case
The Miami Project to Cure Paralysis
By: Robert Steven Kaplan, Christopher Marquis and Brent Kazan
Marc Buoniconti is the co-founder of the Miami Project to Cure Paralysis, a nonprofit medical research organization. The project was founded in 1985 by Marc and his father Nick, a former Hall of Fame football player, when Marc suffered a spinal cord injury. In 2007,... View Details
Keywords: Investment; Philanthropy and Charitable Giving; Health Testing and Trials; Leadership; Growth and Development Strategy; Mission and Purpose; Research and Development; Nonprofit Organizations; Health Industry; Miami
Kaplan, Robert Steven, Christopher Marquis, and Brent Kazan. "The Miami Project to Cure Paralysis." Harvard Business School Case 408-003, June 2008. (Revised July 2008.)